clinical trial · NCT07011706
ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
Atopic DermatitisAtopicDermatitisADEczemaATI-045Placebo
brief summary
This study evaluates ATI-045 versus placebo in patients with Moderate-to-Severe Atopic Dermatitis.
started
May 30, 2025
primary completion
Aug 1, 2026
completion
Oct 1, 2026
last updated
Mar 25, 2026
detailed description
A Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ATI-045 in Patients with Moderate-to-Severe Atopic Dermatitis.
official title
A Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ATI-045 in Patients With Moderate-to-Severe Atopic Dermatitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol